WPC
CLGN icon

Waters Parkerson & Co’s CollPlant Biotechnologies CLGN Stock Holding History

Waters Parkerson & Co’s Portfolio CLGN Stock Details CLGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.62K Hold
13,250
– – ﹤0.01% 200
2026
Q1 		$7.1K Hold
13,250
– – ﹤0.01% 188
2025
Q4 		$18.6K Hold
13,250
– – ﹤0.01% 190
2025
Q3 		$35.6K Hold
13,250
– – ﹤0.01% 184
2025
Q2 		$18K Hold
13,250
– – ﹤0.01% 185
2025
Q1 		$34.2K Buy
+13,250
New +$46.7K ﹤0.01% 183

Other funds holding CLGN

PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $838M AUM 14.24% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
SFG
Strive Financial Group Carmel, Indiana $231M AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Waters Parkerson & Co's CLGN Position: Q2 2026 in Review

Waters Parkerson & Co held its CollPlant Biotechnologies (CLGN) position steady in Q2 2026 at 13,250 shares worth $4.62K. The position accounts for ﹤0.01% of the portfolio, ranked #200.

Waters Parkerson & Co first reported a position in CLGN in Q1 2025 and has held it in 6 quarters since. The position peaked at $35.6K in Q3 2025. 7 funds tracked by Wall St. Rank hold CLGN as of Q2 2026.

  • Waters Parkerson & Co held 13,250 shares of CollPlant Biotechnologies worth $4.62K as of Q2 2026.
  • Waters Parkerson & Co left its CollPlant Biotechnologies share count unchanged in Q2 2026.
  • CollPlant Biotechnologies made up ﹤0.01% of Waters Parkerson & Co's portfolio in Q2 2026, its #200 holding.
  • Waters Parkerson & Co first reported a position in CollPlant Biotechnologies in Q1 2025 and has held it in 6 quarters since.
  • Waters Parkerson & Co's CollPlant Biotechnologies position peaked at $35.6K in Q3 2025.
  • 7 funds tracked by Wall St. Rank held CollPlant Biotechnologies as of Q2 2026.

Based on Waters Parkerson & Co's 13F filing for Q2 2026, filed 30 Jul 2026.